These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 31601022)

  • 1. Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer's Disease-Could
    Jasiecki J; Wasąg B
    Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31601022
    [No Abstract]   [Full Text] [Related]  

  • 2. Synergy between the alteration in the N-terminal region of butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer's disease.
    Jasiecki J; Limon-Sztencel A; Żuk M; Chmara M; Cysewski D; Limon J; Wasąg B
    Sci Rep; 2019 Mar; 9(1):5223. PubMed ID: 30914707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine.
    Scacchi R; Gambina G; Moretto G; Corbo RM
    Am J Med Genet B Neuropsychiatr Genet; 2009 Jun; 150B(4):502-7. PubMed ID: 18780301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
    Korabecny J; Spilovska K; Mezeiova E; Benek O; Juza R; Kaping D; Soukup O
    Curr Med Chem; 2019; 26(30):5625-5648. PubMed ID: 29768996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haplotypes of butyrylcholinesterase K-variant and their influence on the enzyme activity.
    Jasiecki J; Żuk M; Krawczyńska N; Jońca J; Szczoczarz A; Lewandowski K; Waleron K; Wasąg B
    Chem Biol Interact; 2019 Jul; 307():154-157. PubMed ID: 31071335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
    Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
    Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
    De Beaumont L; Pelleieux S; Lamarre-Théroux L; Dea D; Poirier J;
    J Alzheimers Dis; 2016 Oct; 54(3):913-922. PubMed ID: 27567841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Butyrylcholinesterase: K variant, plasma activity, molecular forms and rivastigmine treatment in Alzheimer's disease in a Southern Brazilian population.
    Bono GF; Simão-Silva DP; Batistela MS; Josviak ND; Dias PF; Nascimento GA; Souza RL; Piovezan MR; Souza RK; Furtado-Alle L
    Neurochem Int; 2015 Feb; 81():57-62. PubMed ID: 25624079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment.
    Sokolow S; Li X; Chen L; Taylor KD; Rotter JI; Rissman RA; Aisen PS; Apostolova LG
    J Alzheimers Dis; 2017; 56(1):229-237. PubMed ID: 27911294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease.
    Han HJ; Kwon JC; Kim JE; Kim SG; Park JM; Park KW; Park KC; Park KH; Moon SY; Seo SW; Choi SH; Cho SJ
    Eur Neurol; 2015; 73(1-2):23-8. PubMed ID: 25376930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tailored Modeling of Rivastigmine Derivatives as Dual Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer's Disease Treatment.
    Adeowo FY; Oyetunji TP; Ejalonibu MA; Ndagi U; Kumalo HM; Lawal MM
    Chem Biodivers; 2021 Nov; 18(11):e2100361. PubMed ID: 34547176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
    Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
    Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S
    Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer's Disease Treatment.
    Ali B; Jamal QM; Shams S; Al-Wabel NA; Siddiqui MU; Alzohairy MA; Al Karaawi MA; Kesari KK; Mushtaq G; Kamal MA
    CNS Neurol Disord Drug Targets; 2016; 15(5):624-8. PubMed ID: 26996169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
    Duysen EG; Li B; Darvesh S; Lockridge O
    Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Butyrylcholinesterase-K Allele and Apolipoprotein E ɛ4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer's Disease.
    Vijayaraghavan S; Darreh-Shori T; Rongve A; Berge G; Sando SB; White LR; Auestad BH; Witoelar A; Andreassen OA; Ulstein ID; Aarsland D
    J Alzheimers Dis; 2016; 50(2):567-76. PubMed ID: 26757188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment.
    Ferris S; Nordberg A; Soininen H; Darreh-Shori T; Lane R
    Pharmacogenet Genomics; 2009 Aug; 19(8):635-46. PubMed ID: 19617863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.
    Kabir MT; Uddin MS; Begum MM; Thangapandiyan S; Rahman MS; Aleya L; Mathew B; Ahmed M; Barreto GE; Ashraf GM
    Curr Pharm Des; 2019; 25(33):3519-3535. PubMed ID: 31593530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease.
    Yu YF; Huang YD; Zhang C; Wu XN; Zhou Q; Wu D; Wu Y; Luo HB
    ACS Chem Neurosci; 2017 Nov; 8(11):2522-2534. PubMed ID: 28783948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivastigmine-Bambuterol Hybrids as Selective Butyrylcholinesterase Inhibitors.
    Wu J; Tan Z; Pistolozzi M; Tan W
    Molecules; 2023 Dec; 29(1):. PubMed ID: 38202655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.